Additionally, rovalpituzumab-tesirine (Rova-T), a first-in-class antibody–drug conjugate that targets DLL3 to deliver a cytotoxic compound directly to NEPC tumor cells [26], and specific T cell contact antibodies (NCT03319940 and NCT04471727) serve similar role as DLL3 inhibitor, which might reduce the amount of DLL3 on the surface of NEPC cells [109], and inhibit the growth of NEPC. The gene discussed is DLL3; the disease is neoplasm.